BOSTON (Thomson Financial) - Repligen Corp. said Wednesday that its board
approved the repurchase of up to 1.25 million shares of its common stock.
The company currently has 31.2 million shares outstanding and the stock
repurchases will be funded through available cash.
Shares of the Waltham, Mass.-based therapeutics developer closed Tuesday at
$4.75.
Greg Saulnier
gs/pc
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|